## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($328.99)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Who Owns Cencora? Top Shareholders and Recent Insider Activity**
- Source: TIKR.com | 20260105T160756 | Somewhat-Bullish | Relevance: 100%
- Cencora, Inc. (NYSE: COR) is a global pharmaceutical services company with a market value of approximately $65.7 billion. Its shareholder base is dominated by large institutional investors like The Vanguard Group and BlackRock, providing ownership stability. While hedge funds such as Balyasny Asset Management and Millennium Management have increased their positions, recent insider trades appear modest and related to personal portfolio management rather than signaling a shift in future business performance.

**2. Preço-alvo da Cencora reduzido para US$ 360 pelo BofA devido a preocupações com avaliação**
- Source: Investing.com Brasil - Finanças, Câmbio e Investimentos | 20260105T160740 | Somewhat-Bearish | Relevance: 100%
- BofA Securities has reduced its price target for Cencora Inc (NYSE:COR) from $380 to $360, maintaining a Neutral rating due to valuation concerns, despite the company's strong long-term outlook. This adjustment comes even as Cencora recently increased its long-term adjusted operating profit growth target and announced the acquisition of the remaining interests in OneOncology for approximately $5 billion, which has led other analysts to raise their price targets. The BofA noted that Cencora’s current valuation, with a P/E of 41.52 and a high PEG ratio of 7.41, already reflects much of its future growth potential.

**3. Cencora Inc.: Quiet Rally, Strong Fundamentals – Is This Healthcare Stock Underappreciated?**
- Source: AD HOC NEWS | 20260104T021600 | Bullish | Relevance: 100%
- Cencora Inc. has seen a quiet, sustained rally, reflecting strong fundamentals and investor confidence in its resilient earnings and predictable cash flow within the pharmaceutical supply chain. The company's strategic focus on specialty distribution and biosimilars, coupled with investments in technology, positions it for continued appreciation. Analysts generally hold a bullish view, seeing meaningful upside despite the stock trading near its 52-week high, indicating Cencora as a valuable compounder for long-term portfolio builders.

**4. Cencora stock price target lowered to $360 by BofA on valuation concerns**
- Source: Investing.com Australia | 20260105T161906 | Somewhat-Bearish | Relevance: 100%
- BofA Securities has lowered its price target for Cencora Inc. (NYSE:COR) to $360 from $380, maintaining a Neutral rating due to valuation concerns, despite the company's strong long-term outlook. The adjustment reflects a contraction in peer multiples and the stock currently trading at a premium relative to its growth rate, according to InvestingPro metrics. This contrasts with several other firms like Evercore ISI, TD Cowen, UBS, and Leerink Partners, which recently raised their price targets for Cencora following its acquisition announcement of OneOncology and positive guidance.

**5. B of A Securities Lowers Price Target for Cencora (COR), Maintai**
- Source: GuruFocus | 20260105T141854 | Neutral | Relevance: 100%
- B of A Securities has lowered its price target for Cencora (COR) from $380.00 to $360.00, while maintaining a Neutral rating on the stock. This adjustment reflects a 5.26% decrease, despite other analysts recently raising their price targets for the pharmaceutical wholesaler. The average target price from 16 analysts is $386.97, implying a 14.19% upside from the current price, while GuruFocus estimates a GF Value of $294.68, suggesting a 13.04% downside.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | B of A Securiti | $360 | $380 | -5% |
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | B of A Securiti | main | Neutral |
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.80 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.1B |
| Beta | 0.67 |
| 52W Range | $227.95 - $377.54 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.80 |
| Forward P/E | 17.5 |
| Current P/E | 19.5 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.3% to 0.4% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.41% (CS: 46) | Neutral |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $340.99
- **Stop Loss:** $328.99 (3.5% risk)
- **Target:** $352.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 71
- **Position Value:** $24,210.29
- **Portfolio %:** 24.21%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*